Related Experiment Video
Updated: Apr 21, 2026
08:29
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
9.3K
Development of biodegradable nanoparticles for liver-specific ribavirin delivery
Tsutomu Ishihara1, Kohei Kaneko1, Tomoaki Ishihara2
1Department of Chemical Biology and Applied Chemistry, College of Engineering, Nihon University, Fukushima 963-8642, Japan.
Journal of Pharmaceutical Sciences
|October 23, 2014
Summary
Biodegradable nanoparticles effectively deliver ribavirin monophosphate (RMP) for chronic hepatitis C treatment. This drug delivery system targets the liver and provides sustained ribavirin release, potentially reducing side effects.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Hepatology
Background:
- Ribavirin is a key antiviral for chronic hepatitis C but causes severe hemolytic anemia.
- Developing effective drug delivery systems is crucial to mitigate ribavirin's toxicity and improve therapeutic outcomes.
Purpose of the Study:
- To engineer biodegradable nanoparticles for enhanced ribavirin pharmacokinetics and targeted liver delivery.
- To create a novel drug carrier system for sustained release of ribavirin monophosphate (RMP).
Main Methods:
- Biodegradable nanoparticles encapsulating RMP were synthesized using poly(d,l-lactic acid) and arabinogalactan-poly(l-lysine) conjugate via solvent diffusion with iron (III).
- Nanoparticle characterization included zeta potential measurements and lectin-based aggregation tests to confirm arabinogalactan coating.
- In vitro studies assessed RMP release kinetics and cellular uptake in HepG2 cells.
- In vivo studies in mice evaluated liver accumulation and sustained release of ribavirin post-intravenous administration.
Main Results:
- RMP was efficiently encapsulated and stably released from nanoparticles over 37 days.
- Arabinogalactan coating was confirmed, and nanoparticles showed efficient internalization by HepG2 cells.
- Intravenous administration of RMP-loaded nanoparticles resulted in significant liver accumulation in mice with sustained drug levels for at least 7 days.
Conclusions:
- Successfully developed dual-function nanoparticles for targeted liver delivery and sustained ribavirin release.
- This nanoparticle strategy shows promise for advancing the clinical use of ribavirin in treating chronic hepatitis C.
- The study highlights a potential method to improve ribavirin's therapeutic index by modulating its pharmacokinetic profile.
